Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Product: Intact Protein Analysis System

By Drug Discovery Trends Editor | September 13, 2013

Thermo Scientific Exactive Plus LC-MS. (Source: Thermo Fisher Scientific)Less than four months after introducing important new core Tribrid and triple quadrupole liquid chromatography-mass spectrometry (LC-MS) platforms built to transform customers’ work with unprecedented performance and ease of use, Thermo Fisher Scientific introduces two additional systems designed to advance intact protein analysis and “quanfirmation.” The new technology will be displayed at the 12th HUPO World Congress at the Pacifico Yokohama in booth 51 from Sept. 14-18, 2013. 
 
New technology launched at HUPO includes:
 
  • Extended Mass Range (EMR) option for the Thermo Scientific Exactive Plus LC-MS: Proteomics scientists now have a powerful new tool for challenging high resolution accurate mass (HRAM) intact protein analysis such as investigating the structure, topology and architecture of targets. These include impurities in monoclonal antibodies, antibody-drug conjugates, PEGylated proteins, oligomerized protein-based drugs, glycoforms and protein assemblies. 
     
  • Thermo Scientific Q Exactive Plus LC-MS: The mass spectrometry community first learned about “quanfirmation” (the ability to characterize, quantify and confirm a molecule using one instrument) in 2011 with the debut of the Thermo Scientific Q Exactive hybrid LC-MS. Now, the company is introducing the second generation of this benchtop hybrid HRAM instrument, the Thermo Scientific Q Exactive Plus LC-MS to further increase performance for applications such as bottom-up proteomics, lipidomics and high-confidence DMPK qual/quan screening studies.
 
Date: September 13, 2013
Source: Thermo Fisher Scientific

Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE